Equity Profile

TEVA

Teva Pharmaceutical Industries Limited

Health CarePharmaceuticals$39.8B

Jul29Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Teva Pharmaceutical Industries Limited is a global leader in the pharmaceutical sector, specializing in generic and specialty medications. With a market cap of $41 billion, Teva plays a crucial role in healthcare by providing affordable medicines and addressing various health conditions.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to increase sales and market share, which is vital for sustaining long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TEVA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+15.61%

Avg Stock Reaction

+3.79%

Last Quarter Recap

In Q1-2026, Teva reported an EPS of $0.53, exceeding expectations by 8.83%. The stock reacted positively, gaining 11.89% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Teva's upcoming earnings, given its strong track record of beating EPS estimates.

Bull Case

If Teva continues its trend of beating EPS estimates, it could signal robust operational performance and increased investor confidence.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of declining revenue, it could lead to a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given Teva's history of beating EPS estimates, this figure will be crucial in determining market sentiment.

How is Teva addressing competition in the generic drug market?

Understanding Teva's competitive strategy will provide insights into its future growth potential and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Teva's ability to leverage its generics portfolio effectively, leading to stronger-than-expected revenue growth.

Supporting Evidence

Teva has consistently beaten EPS estimates, indicating potential for continued outperformance.

The options market is pricing a smaller move than historical averages, suggesting a potential miscalculation in volatility expectations.

Key Risk

If Teva's EPS exceeds $0.55, it could challenge the current cautious sentiment and drive stock prices higher.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on Teva's ability to maintain its earnings momentum amidst competitive pressures.

Bull Confirmed If

An EPS of $0.55 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $0.50 would confirm the bear case, raising concerns about the company's profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±5.66%

Historical Avg

±9.0%

Pricing cheap

The options market is pricing in a potential move of about 5.66%, suggesting that investors expect some volatility around the earnings announcement.

Options are pricing ±5.7% while TEVA has averaged ±9.0% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.4%

30d HV

39.9%

Calls (108K)P/C Ratio: 0.30Puts (114K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Teva beats expectations, history suggests a potential stock increase of around 3.79%, confirming strong operational health.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity.

Miss

A miss could lead to a decline, with historical patterns suggesting an average drop of around 3.79%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in the generics segment.
2Management's commentary on cost management strategies.
3Insights into market share changes in key therapeutic areas.
4Updates on regulatory approvals for new drugs.
5Any guidance on future revenue growth expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

Insider activity

PreviewView

Jul

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to increase sales and market share, which is vital for sustaining long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TEVA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+15.61%

Avg Stock Reaction

+3.79%

Last Quarter Recap

In Q1-2026, Teva reported an EPS of $0.53, exceeding expectations by 8.83%. The stock reacted positively, gaining 11.89% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Teva's upcoming earnings, given its strong track record of beating EPS estimates.

Bull Case

If Teva continues its trend of beating EPS estimates, it could signal robust operational performance and increased investor confidence.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of declining revenue, it could lead to a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given Teva's history of beating EPS estimates, this figure will be crucial in determining market sentiment.

How is Teva addressing competition in the generic drug market?

Understanding Teva's competitive strategy will provide insights into its future growth potential and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Teva's ability to leverage its generics portfolio effectively, leading to stronger-than-expected revenue growth.

Supporting Evidence

Teva has consistently beaten EPS estimates, indicating potential for continued outperformance.

The options market is pricing a smaller move than historical averages, suggesting a potential miscalculation in volatility expectations.

Key Risk

If Teva's EPS exceeds $0.55, it could challenge the current cautious sentiment and drive stock prices higher.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on Teva's ability to maintain its earnings momentum amidst competitive pressures.

Bull Confirmed If

An EPS of $0.55 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $0.50 would confirm the bear case, raising concerns about the company's profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±5.66%

Historical Avg

±9.0%

Pricing cheap

The options market is pricing in a potential move of about 5.66%, suggesting that investors expect some volatility around the earnings announcement.

Options are pricing ±5.7% while TEVA has averaged ±9.0% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.4%

30d HV

39.9%

Calls (108K)P/C Ratio: 0.30Puts (114K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Teva beats expectations, history suggests a potential stock increase of around 3.79%, confirming strong operational health.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity.

Miss

A miss could lead to a decline, with historical patterns suggesting an average drop of around 3.79%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in the generics segment.
2Management's commentary on cost management strategies.
3Insights into market share changes in key therapeutic areas.
4Updates on regulatory approvals for new drugs.
5Any guidance on future revenue growth expectations.